Business
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
INCHEON, Korea, January 02, 2026--Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.
About this update from Biogen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1270,"height":458,"url":"https://media.zenfs.com/en/business-wire.com/17900ff8ab97fe67d1730b50a68da90e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Qo8lpKrQ7lPbnLe.3deZ6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/17900ff8ab97fe67d1730b50a68da90e","width":960,"height":346},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1KyKAJdEZqQ.r4r2TCFYuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/17900ff8ab97fe67d1730b50a68da90e","width":1200,"height":433}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®","length":109,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)","length":170,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026","length":97,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":376,"olType":false},{"type":"text","content":"INCHEON, Korea, January 02, 2026--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries.","length":425,"tagName":"p"},{"type":"text","content":""This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabili...